← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Tomegavax, Inc.
Beaverton, OR
$8,446,827
Total funding
8
Grants
Funding over time
peak $2.2M · FY2012–19$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$8,446,827 · 8
By mechanism
R44$6,824,439 · 3
R41$872,923 · 2
R43$749,465 · 3
Investigators at Tomegavax, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B$1,000,000
R44 · FY2019 · AI
A human cytomegalovirus-based immunotherapy for HIV-1$992,696
R44 · FY2014 · AI
A human cytomegalovirus-based immunotherapy for HIV-1$986,519
R44 · FY2015 · AI
A human cytomegalovirus-based immunotherapy for HIV-1$986,188
R44 · FY2016 · AI
A Cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses$948,184
R44 · FY2016 · CA
A Cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses$928,329
R44 · FY2017 · CA
A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B$685,089
R44 · FY2018 · AI
A Synthetic Human Cytomegalovirus Vaccine Platform$300,000
R41 · FY2013 · AI
CMV Vectored Herpes Simplex Vaccine$299,863
R41 · FY2014 · AI
Spread-deficient HCMV-vectored vaccines$299,835
R43 · FY2012 · AI
A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B$297,434
R44 · FY2017 · AI
A Synthetic Human Cytomegalovirus Vaccine Platform$273,060
R41 · FY2014 · AI
A Cytomegalovirus Vectored Chagas Disease Therapeutic Vaccine$224,959
R43 · FY2016 · AI
An effector memory T cell-based therapeutic cervical cancer vaccine$224,671
R43 · FY2014 · CA